Blueshift Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Blueshift Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$638K	Buy	+2,118	New	+$639K	0.15%	140
2026 Q1	–	Sell	-791	Closed	-$315K	–	495
2025 Q4	$315K	Buy	791 +188	+31%	+$83.2K	0.09%	317
2025 Q3	$275K	Buy	+603	New	+$246K	0.08%	333
2025 Q1	–	Sell	-1,698	Closed	-$400K	–	389
2024 Q4	$400K	Buy	1,698 +631	+59%	+$166K	0.15%	198
2024 Q3	$293K	Buy	+1,067	New	+$278K	0.07%	284
2023 Q3	–	Sell	-3,763	Closed	-$715K	–	273
2023 Q2	$715K	Buy	+3,763	New	+$746K	0.27%	95
2022 Q2	–	Sell	-5,506	Closed	-$899K	–	662
2022 Q1	$899K	Sell	5,506 -196	-3%	-$29.9K	0.08%	293
2021 Q4	$967K	Buy	5,702 +2,276	+66%	+$423K	0.09%	309
2021 Q3	$647K	Buy	+3,426	New	+$643K	0.04%	542
2021 Q2	–	Sell	-6,447	Closed	-$910K	–	903
2021 Q1	$910K	Buy	6,447 +3,730	+137%	+$561K	0.09%	296
2020 Q4	$353K	Buy	+2,717	New	+$363K	0.04%	490

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blueshift Asset Management's ALNY Position: Q2 2026 in Review

Blueshift Asset Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 2,118 shares worth $638K. The stake represents 0.15% of the portfolio and ranks #140 among its holdings. This is a return to the name: Blueshift Asset Management previously reported a position in ALNY as recently as Q4 2025.

Blueshift Asset Management first reported a position in ALNY in Q4 2020 and has held it in 11 quarters since. The position peaked at $967K in Q4 2021. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Blueshift Asset Management held 2,118 shares of Alnylam Pharmaceuticals worth $638K as of Q2 2026.
Alnylam Pharmaceuticals was a new Blueshift Asset Management position in Q2 2026.
Alnylam Pharmaceuticals made up 0.15% of Blueshift Asset Management's portfolio in Q2 2026, its #140 holding.
Blueshift Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
Blueshift Asset Management's Alnylam Pharmaceuticals position peaked at $967K in Q4 2021.
785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.